Total Plaque Volume Test

You can have completely normal cholesterol, a clean stress test, and a calcium score of zero, and still have meaningful plaque silently building up in the walls of your heart's arteries. Total plaque volume is the imaging measurement that finally puts a real number on how much of that buildup is actually there.

Standard heart tests check risk factors or look for narrowing severe enough to block blood flow. This test, taken from a coronary CT angiogram (a CT scan that injects contrast dye to map your heart arteries), directly measures the total volume of plaque inside the artery walls, calcified and non-calcified combined, across the entire coronary tree.

What This Number Actually Shows

TPV (total plaque volume) is the summed three-dimensional volume of every plaque deposit found in your coronary arteries, reported in cubic millimeters. It is calculated by special software, often AI-driven, that traces the inner and outer wall of each artery segment and measures the tissue sitting between them.

What makes TPV powerful is that it captures the full plaque picture, not just the visible narrowing of the artery. Most heart attacks happen at plaques that were not severely narrowing the artery beforehand. TPV sees those non-obstructive plaques, counts them, and gives you a total burden number that tracks much more closely with future heart attack risk than stenosis percentage alone.

Why Plaque Volume Beats Calcium Alone

A coronary calcium score (CAC) only counts calcified plaque, the older, harder, more stable kind. Soft plaque made of fat, inflammation, and fibrous tissue, the kind most likely to rupture and cause a heart attack, does not show up on a calcium score at all.

Studies of people with a calcium score of zero have found that meaningful amounts of non-calcified plaque can still be present, and that this hidden burden carries real risk. TPV captures both kinds, which is why it tends to outperform calcium scoring for predicting future cardiovascular events in head-to-head comparisons. In one large registry of patients with suspected coronary disease, CT-measured plaque burden gave more accurate prognostic information for future adverse events than a calcium score did.

Heart Attack and Cardiovascular Event Risk

The link between plaque volume and hard cardiovascular outcomes is one of the most consistent findings in modern cardiology imaging research. The more plaque you have packed into your coronary tree, the more likely you are to have a heart attack or die from cardiovascular causes in the years ahead, even after accounting for traditional risk factors.

In a study of 1,611 patients from the SCOT-HEART trial followed for nearly five years using AI-analyzed coronary CT scans, those with plaque volumes at or above roughly 238 cubic millimeters had about 5.4 times the risk of a future heart attack compared with people below that threshold, independent of stenosis severity and standard risk scores. In the ISCHEMIA trial of more than 3,700 patients with moderate-to-severe coronary disease, plaque volume was the strongest single plaque-based predictor of cardiovascular death or heart attack, and adding plaque quantification to clinical risk factors meaningfully improved event prediction.

What this means for you: if your TPV comes back elevated, your risk of a heart attack in the next several years is genuinely higher than your standard cholesterol panel or your calcium score might suggest, and that is true even if you feel completely fine and have never had a cardiac symptom.

Ischemia and Functional Disease

Beyond predicting events, TPV correlates with whether your heart is actually being starved of blood flow. A meta-analysis of coronary CT studies found that higher total and percent plaque volumes were tightly associated with abnormal fractional flow reserve (a direct test of whether a blockage is restricting blood flow). In other words, the more plaque, the more likely some of it is functionally significant.

Sex Differences

Plaque volume tends to be higher in men than women at any given age. In a large international cohort of nearly 12,000 people scanned, men had a median TPV of 360 cubic millimeters versus 108 in women. But here is the counterintuitive part: for every 50-cubic-millimeter increase in plaque volume, the relative jump in cardiovascular event risk is larger in women than in men. Women appear to be more vulnerable per unit of plaque.

This isn't actually a paradox once you understand the framing. Men carry more plaque on average, so the population-level burden of heart disease is higher in men. But for an individual woman with a given plaque load, that load is doing more damage to her than the same load would do in a man. The practical implication: a woman should not feel reassured by a plaque volume that would be considered moderate in a man.

Research-Based Reference Ranges

There is no single universal cutoff for TPV. The values below come from CT angiography studies that proposed plaque-volume stages aligned with how much underlying disease and ischemia was present. These ranges are best used as orientation, not as fixed targets. Different scanners, contrast protocols, and AI software can give different numbers for the same person.

Sources: Min et al. 2022 (303 patients, CCTA with invasive angiography and FFR); Nurmohamed et al. 2024 (ISCHEMIA, 3,711 patients). Reference values are also shaped by age and sex; in one international cohort of 11,808 people, median TPV was 223 mm³ overall, 360 in men, and 108 in women, with plaque rising steadily with age. Compare your results within the same lab and software platform over time for the most meaningful trend.

Tracking Your Trend Matters More Than One Reading

A single TPV number tells you where you stand today. What it cannot tell you is whether your plaque is stable, growing, or shrinking. In a long-term observational study of more than 1,500 people, having a higher TPV at baseline strongly predicted 10-year outcomes, but the rate of change over time mattered just as much for risk.

In type 2 diabetes, average annual plaque progression has been measured at roughly 13.4 percent of baseline volume, with more than a third of patients progressing at 15 percent or more per year. Treatment can dramatically slow or reverse this. Meta-analysis of lipid-lowering therapy trials shows that for every 1 percent reduction in plaque volume achieved, the odds of a major adverse cardiovascular event drop by about 25 percent. That means plaque change is not just a number on a scan, it is a directly modifiable predictor of whether you have a heart attack.

A reasonable cadence: get a baseline, repeat in 12 to 24 months if you are actively making changes to your lipids, blood pressure, or lifestyle, then every 2 to 5 years depending on your trajectory. The radiation dose of modern coronary CT is low enough that serial scanning every few years is reasonable for most people who are at meaningful risk.

When Results Can Be Misleading

• Scanner and software differences: total plaque volume measurements depend on tube voltage, contrast injection rate, image reconstruction settings, and the specific AI or semi-automated software used to trace the artery walls. Two scans from different centers can produce different numbers on the same person, which is why comparing within the same lab and platform matters.
• Heart rate and motion artifact: a fast or irregular heart rate at the time of the scan can blur the images and make plaque measurement less accurate. Most centers will give beta-blockers before the scan to slow your heart rate to roughly 60 beats per minute.
• Severe calcification: very dense calcium deposits can create a 'blooming' artifact that makes nearby plaque appear larger than it really is. Newer photon-counting CT scanners reduce this distortion but most centers still use older technology.
• Recent stent placement: metal stents create artifacts that make plaque quantification in or near the stented segment unreliable, which is why TPV is most useful before any intervention.

What to Do If Yours Is Elevated

An elevated TPV is not just a number to file away. It is an actionable diagnosis of subclinical coronary artery disease, even if you have no symptoms. The decision pathway depends on what else is going on.

If your TPV is in stage 1 or higher, the standard preventive workup should be intensified. That means a full lipid panel with ApoB (apolipoprotein B, a more accurate count of atherogenic particles than LDL alone) and Lp(a) (lipoprotein little a, a genetic lipid risk factor often invisible on standard panels), inflammation markers like hs-CRP, and a careful look at blood pressure and glucose. Most people with non-zero plaque volume should be on a statin and likely targeting an LDL cholesterol below 70 mg/dL, with lower targets if plaque is more advanced or progressing. If LDL goals are not met on a statin alone, ezetimibe or a PCSK9 inhibitor (proprotein convertase subtilisin/kexin type 9, a class of injectable cholesterol-lowering drugs) should be added. A consultation with a preventive cardiologist or lipidologist is reasonable for anyone in stage 2 or 3 territory, especially under age 60, because the years of plaque-free arteries you can buy with aggressive treatment are substantial.

If your TPV is at or near zero, your near-term coronary event risk is genuinely low, which is reassuring. But this is a snapshot. People in low-risk categories today can still develop plaque, especially if Lp(a), ApoB, or lifestyle factors are unfavorable. Reassessing in 3 to 5 years makes sense.